MedTrace Logo

The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation

NCT05769738 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-03-15

No results posted yet for this study

Summary

The goal of this randomized controlled trial is to determine the effect of adding inhaled furosemide to the known treatment of patient with Chronic obstructive pulmonary disease (COPD) exacerbation. It primarily aims at studying its effect on:

1. Relief of dyspnea sensation
2. Length of hospital stay

Participants will be receiving the standard therapy of COPD exacerbation plus either inhaled furosemide or inhaled saline over 3 days. They will be asked to:

* Perform spirometry
* Fill in dyspnea score
* Do arterial blood gases (ABGs)

Conditions

  • Chronic Obstructive Pulmonary Disease Exacerbation
  • COPD Exacerbation

Interventions

DRUG

Furosemide

40mg (4ml) of furosemide to be nebulized 3 times daily for 3 days

DRUG

Normal saline

4ml of normal saline to be nebulized 3 times daily for 3 days

Sponsors & Collaborators

  • American University of Beirut Medical Center

    lead OTHER

Principal Investigators

  • Nivine Abou Dargham, MD · AUBMC

  • Salah Zeineddine, MD · AUBMC

  • Hisham Bou Fakhreddine, MD · AUBMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2024-12-31
Completion
2024-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05769738 on ClinicalTrials.gov